1. A pharmaceutical composition for inhalation containing aclidinium in the form of a dry powder of a pharmaceutically acceptable salt mixed with a pharmaceutically acceptable carrier in the form of a dry powder, which contains a measured nominal dose of aklidinium equivalent to about 400 μg of aklidinium bromide. The pharmaceutical composition according to claim 1 in the form of a single dose formulation in the form of a dry powder containing one measured nominal dose of aklidinium equivalent to about 400 μg of aklidinium bromide. The pharmaceutical composition of claim 1 in the form of a multi-dose dry powder formulation for administration with a multi-dose dry powder inhaler device that is calibrated to provide a metered nominal dose of aklidinium equivalent to about 400 μg of aklidinium bromide. A pharmaceutical composition according to one of the preceding claims, wherein the pharmaceutically acceptable salt of aklidinium is aklidinium bromide. The pharmaceutical composition according to PP. 1-3, in which the pharmaceutically acceptable carrier is lactose particles. The pharmaceutical composition according to PP. 1-3, in which the mass ratio of aclidinium and carrier is from 1:25 to 1: 75.7. The pharmaceutical composition according to claim 6, in which the mass ratio of aclidinium and carrier is from 1:50 to 1: 75.8. The pharmaceutical composition according to PP. 1-3, in which the average particle diameter of aclidinium is 2-5 microns. 9. The pharmaceutical composition according to PP. 1-3, in which the carrier particles are characterized by a d10 value of 90-160 μm, a d50 value of 170-270 μm, and a d90 value of 290-400 μm. 10. The pharmaceutical composition according to PP. 1-3, which with1. Фармацевтическая композиция для ингаляции, содержащая аклидиний в форме сухого порошка фармацевтически приемлемой соли в смеси с фармацевтически приемлемым носителем в форме сухого порошка, которая содержит отмеренную номинальную дозу аклидиния, эквивалентную примерно 400
